• Home
  • Industry News
  • SoCal’s Arrowhead Pharma Stock Craters After Terminating 30% of Workforce, Discontinuing Work on Lead Hep B Drugs

SoCal’s Arrowhead Pharma Stock Craters After Terminating 30% of Workforce, Discontinuing Work on Lead Hep B Drugs


November 30, 2016By Mark Terry, BioSpace.com Breaking News Staff Pasadena, Calif. – Arrowhead Pharmaceuticals (ARWR) announced that it is halting three clinical programs and laying off about 30 percent of staff. On November 7, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Heparc-2004 based on nonclinical toxicology studies of the company’s […]
Source link